The Viatris manufacturing plant in Little Island which employs more than 230 staff.

Pharma giant to close Cork site

A pharmaceutical company employing more than 230 people has announced it will close its manufacturing plant in Cork.

Viatris, which has a plant in Little Island, employs close to 1,600 people across five sites in Ireland in areas such as engineering, manufacturing, commercial, and research and development.

However, the company has said the closure will not happen until 2028.

SIPTU representatives have requested an urgent meeting with the management of Viatris, following its announcement today.

SIPTU Organiser, Ciara McMahon-Flavin, said: “This announcement is a shocking development for our members, many of whom have provided decades of loyal service to the company at this plant. The announcement was unexpected and we are seeking an urgent meeting with the company to discuss all options to ensure the future of operations at this site.”

She added: “The plant has provided quality unionised jobs and their loss would be devastating to our members and their families. We are also calling for Government intervention in an attempt to save this plant and its jobs.”

Responding to the announcement, Director of Public Affairs at Cork Chamber, Cathal McSweeney, said he remains “very optimistic” those affected will find new employment opportunities.

He said: “The job losses announced at Viatris present a challenging situation for all involved and we empathise with those affected by this unfortunate situation.

“It offers some help that no job will be lost until 2028, and in recent times.

“The extensive pharma and life sciences ecosystem in Cork, encompassing R&D, education, and the business network, remains strong,” added Mr McSweeney.

The site in Little Island consists of an API and oral solid dosage (OSD) manufacturing facility where staff produce active pharmaceutical ingredient and OSD medicines.

Mr McSweeney continued: “The site occupied by Viatris in Little Island has a long history in serving the pharma industry and we would be confident that it offers great potential for future development.”